Skip to content

Mensenchymal Stem Cell (MSC) Included in OrthADAPT Membrane for Rotator Cuff Tears Repair

Treatment of Rotator Cuff Tears Using Autologous Bone Marrow Mensenchymal Stem Cell Transplantation.

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01687777
Acronym
msctendonrep
Enrollment
10
Registered
2012-09-19
Start date
2010-05-31
Completion date
2013-12-31
Last updated
2012-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Disease

Keywords

Supraspinatus tendon, Mesenchymal stem cells, OrthADAPT, Rotator cuff

Brief summary

Surgical reconstructive procedures for rotator cuff tears present a number of limitations. The few studies in which the repair integrity is evaluated, have shown the existence of a high rate of reruptures in spite of the fact that the functional results obtained short-term are satisfactory. Morphologic analysis from the sutures, after different follow-up periods, has not shown satisfactory results. Thus, the purpose of the current study was to test the hypotheses that mesenchymal stem cells (MSCs) included in a membrane into rotator cuff tears improves, the radiograms and the function compared to cell-free tendon defect treatment.

Detailed description

The investigators will include: Patients with massive tears from the supraspinatus tendon, in which reconstructive surgery is indicated. Patients will be randomly stratified into two groups. The first group will receive autologous MSCs transplantation included in a collagen type I membrane (OrthADAPT) and the second group will serve as cell-free controls. The surgical procedure will be performed by arthroscopic and/or combined technique: arthroscopic subacromial decompression and mini-open rotator cuff repair. The OrthADAPT-cells composite will be put on the sutured area. The radiograms and function will be assessed by independently observers, who will no have knowledge of the study group from which they will have been obtained.

Interventions

20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.

BIOLOGICALOrthADAPT

Sponsors

Hospital General Universitario Gregorio Marañon
CollaboratorOTHER
Hospital San Carlos, Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
55 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Subject providing informed consent. * Comprised subject male/female aged 55-80. * Subject has a supraspinatus tendon rupture. * Subject has an unilateral injury. * Rupture is enough to need medical assistance. * Subject has an conventional medical treatment fail at least 3 months. * Subject has a reparable injury according to Goutallier´s criteria.

Exclusion criteria

* Subject has a prior clinical history of arthritis, diabetes or inflammatory disease.

Design outcomes

Primary

MeasureTime frame
Constant Shoulder Scoreup to 1 year

Secondary

MeasureTime frame
Nuclear Magnetic Resonance (RMN)6 months, one year

Countries

Spain

Contacts

Primary ContactBenjamín Fernández-Gutiérrez, PhD
bfernandez.hcsc@salud.madrid.org+34913303615
Backup ContactPilar Tornero-Esteban, PhD
mptornero@gmail.com+34913303615

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026